Houston Texans rookie John Metchie makes leukemia diagnosis public: ‘Probably won’t be able to play in 2022’

John Metchie III is suffering from leukemia. This diagnosis of their receiver was spread by the Houston Texans. He will likely only see the 2022 season as a spectator, but a cure from the deadly disease seems realistic.

Munich – Football is secondary for John Metchie III in the midst of preparing for his first NFL season. That’s because the Houston Texans’ second-round pick has leukemia. The franchise made that public with a statement from the 22-year-old.

In it, the wide receiver is quoted as saying: “I was recently diagnosed with APL (acute promyelocytic leukemia), the most curable form of leukemia.” However, APL too is fatal if left untreated.

Metchie has leukaemia and ticks off 2022 season

Metchie goes on to say that he is currently receiving the best possible care, that he is “in good spirits” and that he hopes to make a full recovery. However, this will take time: “As a result of the diagnosis, I probably won’t be able to play this season.”

His focus is now on his full recovery. The Taiwanese-born professional, who came to the USA via Ghana and Canada, is also grateful for the wishes of recovery and, in spite of everything, rejoices: “I can’t wait to come back stronger than ever before.

Metchie suffered a torn ACL in college

Metchie recommended himself the past three years with Alabama Crimson Tide, for whom he caught passes for 1142 yards and eight touchdowns in 2021 before tearing his ACL in the SEC Championship Game.

The Texans drafted him 44th overall, the ninth receiver of the year, and the BC Lions had previously selected him to the CFL.

He should be encouraged by the case of Chuck Pagano. In 2012, the then head coach of the Indianapolis Colts had also received an APL diagnosis. He had to retire for three months, but was back on the sidelines during the playoffs.

Author
Published
2 years ago
Categories
AFC
Comments
No Comments

Leave a Reply

Your email address will not be published. Required fields are marked *